Table D15. Medication adherence subgroup outcomes, part 1

| **Author, Year**  **Trial Name** | **Subgroup** | **Specific subgroup** | **Medication Adherence Outcome 1 for subgroup** | **Description of Timing of Measurement of Adherence Outcome** | **Data source** | **N** | **Results** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Bogner et al., 20084 NA | Hypertension comorbidity | Hypertension comorbidity | Depression adherence: % of prescribed doses taken; calculated as number of doses taken divided by the number  of doses prescribed during the observation period multiplied by 100% - dichotomized with 80% threshold | Measured over 6 week study period for entire study period | MEMS | G1: 32 G2: 32 | G1: 23 (71.9) G2: 10 (31.3) 95% CI,  p: .001 |
| Bogner et al., 20105 NA | Older African American primary care patients | Older African American primary care patients | >80% adherence to an oral hypoglycemic agent | 4 times, biweekly beginning at baseline and ending at week 6 | MEMS | G1: 29 G2: 29 | **BL** G1: 10 (34.5%) G2: 6 (20.7%)  95% CI, NR p: 0.19  **EP** **at 6 weeks** G1: 18 (62.1%) G2: 7 (24.1%) 95% CI, NR p: 0.004 |
| Fulmer et al., 199915 NA | Elderly | Elderly | Percent of prescribed medication doses taken | Adherence was monitored during a 2-week pre-intervention phase, 6-week intervention phase (time 2), and 2-week post-intervention phase (time 3) | MEMS | G1: 17 G2: 15 G3: 18 | **Average compliance rates at BL** G1: 82% G2: 76% G3: 81%  **Average compliance rates at time 3** G1: 84% G2: 74% G3: 57% (significantly decreased from baseline at p<0.04) 95% CI,  p: There was a statistically significant time effect during the course of the study from baseline to post-intervention (F=4.08, p<0.05). Over time, G1 and G2 showed enhanced compliance relative to G3. However, there was no significant difference between G1 and G2. |
| Katon et al., 199524 NA | Major depression | Major depression | % receiving adequate dosage of antidepressants for ≥30 days (details NR) | during continuation phase of treatment (3-7 months) | PRD | **Major depression group**  N=91  **Minor depression group**  N=126 | **Major depression group**  G1: 87.8  G2: 57.1  95% CI, NR  p: <0.001  **Minor depression group**  G1: 88.1  G2: 47.8  95% CI, NR  p: <0.001 |
| Katon et al., 199625 NA | Major depression | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction |
| Katon et al., 199926 NA  Katon et al., 200227 NA | Severity of Depression  (reported in 3169 Katon) | Severe depression (Defined as SCL-20 score >2.0 at baseline) | Adherence to adequate dosage of antidepressants for at least 90 days out of previous six months | Timeframe: six months; measured 5 times in 6 month-intervals until 30 months after randomization (at 6, 12, 18, 24, 30 months) | PRD | Overall N: 79 G1: NR G2: NR | **At 6 months**:  G1: 24 (72%) G2: 14 (40%) Chi-square (1) = 8.23 p: < 0.01  **At 12 months**:  G1: 23 (70%) G2: 13 (37%) Chi-square (1) = 5.98 p: < 0.05  For 18-, 24- and 30-months: "the percentages were very similar for the treatment groups" |
| Lee et al., 200631 FAME | Elderly (≥65 years old) | Elderly (≥65 years old) | % medication adherence at 14 months (proportion of pills taken), mean (SD) | Total timeframe of 6 month average (months 8-14);  G1 - 3 pill counts every 2 months; G2 - 1 pill count at the end of 6 months | Pill count | G1: 83 G2: 76 | G1: 95.5 (7.7) G2: 69.1 (16.4) 95% CI, NR p<0.001 |
| Lin et al., 200632 NA | Depression comorbidity | Depression comorbidity | Percentage of days nonadherent | Measured 2 times over a 12-month period | PRD | Oral hypoglycemic agent  **BL**  G1: 103 G2: 103  **EP**  G1: 103  G2: 103  ACE inhibitor  **BL**  G1: 54  G2: 65  **EP**  G1: 59  G2: 52  Lipid-lowering agent  **BL**  G1: 50  G2: 52  **EP**  G1: 54  G2: 63 | Oral hypoglycemic agent  **BL** (%) (Mean (SD))  G1: 19.8% (21.3%)  G2: 22.9% (24.0%)  95% CI, NR  p: NS  **EP** (%) (Mean (SD))  G1: 28.2% (28.9%)  G2: 24.0% (24.7%)  95% CI, NR  p: <0.03  ACE inhibitor  **BL** (%) (Mean (SD))  G1: 27.4% (27.1%)  G2: 29.7% (29.3%)  95% CI, NR  p: NS  **EP** (%) (Mean (SD))  G1: 24.2% (22.7%)  G2: 18.9% (17.4%)  95% CI, NR  p: NS  Lipid-lowering agent  **BL** (%) (Mean (SD))  G1: 29.3% (26.7%) G2: 24.5% (23.0%)  95% CI, NR  p: NS  **EP** (%) (Mean (SD))  G1: 28.8% (27.1%)  G2: 27.7% (24.0%)  95% CI, NR  p: NS |
| Pyne et al., 201141 HIV Translating Initiatives for Depression Into Effective Solutions (HITIDES) | Entire study is conducted in subgroup with HIV comorbidity | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction |
| Rich et al., 199642 NA | Elderly (≥70 years old) | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction |
| Schneider et al., 200849 NA | Elderly (≥65 years old) | Elderly (≥65 years old) | Percentage of patients who had prescriptions refilled on time (±5 days of due date) | Calculated for all previous months at 6 month and 12 month follow-ups | PRD | SG1: 47  SG2: 38 | Mean (SD)  SG1: 80.4 (21.2)  SG2: 66.1 (28.0)  95% CI, N-R  p: 0.12 |
| Zhang et al., 201067 N/A | Elderly (≥65 years) | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction |